Get the Stockscreener App
0.175
2.02%
-0.0036
Oragenics Inc stock is traded at $0.175, with a volume of 211.26K.
It is down -2.02% in the last 24 hours and down -34.70% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.1786
Open:
$0.18
24h Volume:
211.26K
Relative Volume:
0.05
Market Cap:
$4.07M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0205
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-1.13%
1M Performance:
-34.70%
6M Performance:
-46.14%
1Y Performance:
-83.80%
1-Day Range:
$0.17
$0.18
1-Week Range:
$0.17
$0.2092
52-Week Range:
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.175 | 4.07M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles By Investing.com - Investing.com South Africa
Oragenics Inc. (OGEN) reports earnings - qz.com
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
The Oragenics Inc (OGEN) Stock Is Headed for a Correction - US Post News
Digital Risk Inc. Launches Digital Footprint Exposure Assessment Tool to Combat Human Cybersecurity Risks - The Manila Times
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury - Nasdaq
Oragenics, Inc. Submits Investigator’s Brochure for Phase - GlobeNewswire
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - Yahoo Finance UK
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - The Manila Times
Heritage Distilling Co. Cocoa Bomb Chocolate Whiskey Named 'Best Flavored Whiskey” in the United States at Whisky Magazine's World Whiskies Awards - The Manila Times
Oragenics, Inc. to Present Concussion Treatment Advancements at Emergencies in Medicine Conference - Nasdaq
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health - The Manila Times
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - The Manila Times
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, - GlobeNewswire
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Armenian Reporter
Oragenics, Inc. Announces Partnership with BRAINBox - GlobeNewswire
Oragenics Partners With BRAINBox To Develop Intranasal Therapy For Concussion Treatment - Nasdaq
Irobot Corp (IRBT) Stock: From Low to High in 52 Weeks - The InvestChronicle
Adversity is less terrifying than hope: Oragenics Inc (OGEN) - SETE News
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):